Wunderman names Kessel chief at RTC

Share this article:
WPP-owned Wunderman has named direct marketing veteran Barry Kessel CEO of RTC Relationship Marketing (RTCRM), its Washington, DC, unit.

Kessel, who was previously senior strategist at RTCRM, replaces former CEO Becky Chidester, who left in November 2005 to become COO of Wunderman's New York office.

As RTCRM CEO, Kessel will report directly to Wunderman CEO Daniel Morel.

“Although we are a Wunderman agency, we fly a different flag,” Kessel told MM&M, “and I think we have a different value proposition. So, while we share intellectual property, approaches and practices, we are a different culture.”

Kessel added, “RTCRM is very strong right now. We have been experiencing remarkable growth lately including new business and organic growth from current clients.”

As a result, plans to expand the agency's geographic footprint are in the works. “We have our headquarters in Washington, DC, and an office in New York and we are looking at expansion into Chicago where we have a key client, and there's also some West Coast potential,” he said.
RTCRM's health care roster includes Abbott Laboratories, Sanofi-Aventis, Berlex, GlaxoSmithKline and AARP Services.

Kessel joined Wunderman in 2001 as EVP, global account director on the IBM business and became chief development officer in 2004. He also served as president and managing director of Wunderman New York. Prior to Wunderman, he was with Brann Worldwide and Young & Rubicam, where he was president, chief creative officer of Chapman Direct Advertising and general manager of Stone & Adler in Toronto.

Additionally, 16-year RTCRM executive Jeffrey Ross has been named RTCRM president.
Ross joined RTCRM in 1990. Most recently, he served as executive vice president at the agency.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...